Nalmefene Biogaran (Nalmefene)

Nalmefene blocks μ‑opioid receptors and partially activates κ‑opioid receptors. This dual action reduces the dopamine release that normally follows alcohol intake, thereby decreasing the rewarding and reinforcing effects of alcohol and encouraging reduced consumption.

The specific dose and dosing schedule are determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other relevant factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for nalmefene in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative is naltrexone, another opioid antagonist. Both reduce alcohol‑related cravings, but nalmefene has a mixed μ‑antagonist/κ‑partial‑agonist profile, which may offer a different side‑effect balance and can be used on an as‑needed basis, whereas naltrexone is typically taken daily.

Store the product at temperatures below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Keep the medication out of reach of children and do not use it after the expiry date printed on the label.

Nalmefene Biogaran is administered orally. The tablet should be swallowed whole with a glass of water, preferably on a day when alcohol consumption is anticipated, as directed by the prescribing clinician.

Serious risks include potential hepatic injury (elevated liver enzymes or jaundice), severe allergic reactions such as anaphylaxis, and psychiatric effects like suicidal thoughts or marked mood changes. Patients should report any of these symptoms to their healthcare provider immediately.

Nalmefene is contraindicated in patients with severe hepatic impairment, those currently receiving opioid analgesics, and individuals with known hypersensitivity to the drug. Caution is also advised for patients with renal dysfunction or a history of severe psychiatric disorders.